Skip NavigationSkip to Content

Apoptosis Is the Essential Target of Selective Pressure against p53, whereas Loss of Additional p53 Functions Facilitates Carcinoma Progression

  1. Author:
    Lu, X. D. L. X. D.
    Yang, C. Y.
    Yin, C. Y.
    Van Dyke, T.
    Simin, K.
  2. Author Address

    [Simin, K] Univ Massachusetts, Sch Med, Dept Canc Biol, Worcester, MA 01605 USA [Lu, XD Lu, XD; Yang, CY; Yin, CY] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA [Van Dyke, T] NCI, Frederick, MD 21701 USA;Simin, K (reprint author), Univ Massachusetts, Sch Med, Dept Canc Biol, 364 Plantat St,Lazare Res Bldg 413, Worcester, MA 01605 USA;karl.simin@umassmed.edu
    1. Year: 2011
    2. Date: Apr
  1. Journal: Molecular Cancer Research
    1. 9
    2. 4
    3. Pages: 430-439
  2. Type of Article: Article
  3. ISSN: 1541-7786
  1. Abstract:

    The high frequency of p53 mutation in human cancers indicates the important role of p53 in suppressing tumorigenesis. It is well established that the p53 regulates multiple, distinct cellular functions such as cell-cycle arrest and apoptosis. Despite intensive studies, little is known about which function is essential, or if multiple pathways are required, for p53-dependent tumor suppression in vivo. Using a mouse brain carcinoma model that shows high selective pressure for p53 inactivation, we found that even partially abolishing p53-dependent apoptosis by Bax inactivation was sufficient to significantly reduce the selective pressure for p53 loss. This finding is consistent with previous reports that apoptosis is the primary p53 function selected against during Em-myc-induced mouse lymphoma progression. However, unlike observed in the Em-myc-induced lymphoma model, attenuation of apoptosis is not sufficient to phenocopy the aggressive tumor progression associated with complete loss of p53 activity. We conclude that apoptosis is the primary tumor suppressive p53 function and the ablation of additional p53 pleiotropic effects further exacerbates tumor progression. Mol Cancer Res; 9( 4); 430-9. (C) 2011 AACR.

    See More

External Sources

  1. DOI: 10.1158/1541-7786.mcr-10-0277
  2. WOS: 000289511600005

Library Notes

  1. Fiscal Year: FY2010-2011
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel